Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis

CONCLUSIONS: The plasma fibrinogen levels in patients who were administered batroxobin for hemoptysis should be monitored, and batroxobin should be discontinued if hypofibrinogenemia occurs.PMID:36794140 | PMC:PMC9922611 | DOI:10.21037/jtd-22-717

Source: Journal of Thoracic Disease - February 16, 2023 Category: Respiratory Medicine Authors: Jae-Kyeong Lee Chang-Seok Yoon Young-Ok Na Hwa Kyung Park Hyung-Joo Oh Bo-Gun Kho Ha-Young Park Tae-Ok Kim Hong-Joon Shin Yong-Soo Kwon Yu-Il Kim Sung-Chul Lim Source Type: research